Page last updated: 2024-10-14

bms-663068

Description

fostemsavir: an HIV-1 attachment inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11319217
CHEMBL ID3301594
SCHEMBL ID754395
MeSH IDM0579079

Synonyms (71)

Synonym
HY-15440A
fostemsavir
CS-1059
piperazine, 1-benzoyl-4-((4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-((phosphonooxy)methyl)-1h-pyrrolo(2,3-c)pyridin-3-yl)oxoacetyl)-
bms663068
97iq273h4l ,
unii-97iq273h4l
(3-((4-benzoyl-1-piperazinyl)(oxo)acetyl)-4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo(2,3-c)pyridin-1-yl)methyl dihydrogen phosphate
1,2-ethanedione, 1-(4-benzoyl-1-piperazinyl)-2-(4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-((phosphonooxy)methyl)-1h-pyrrolo(2,3-c)pyridin-3-yl)-
bms-663068 free acid
864953-29-7
bms 663068
bms-663068
fostemsavir [usan]
fostemsavir [who-dd]
(3-((4-benzoylpiperazin-1-yl)-oxoacetyl)-4-methoxy- 7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo(2,3-c)pyridin- 1-yl)methyl dihydrogen phosphate
fostemsavir [inn]
fostemsavir [mi]
S7220
CHEMBL3301594
DTXSID40235596
SCHEMBL754395
[3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate
D10707
fostemsavir (usan)
AC-30663
1,2-ethanedione, 1-(4-benzoyl-1-piperazinyl)-2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-
AKOS025396430
fostemsavir(bms-663068)
compound 35 [pmid: 29271653]
gsk3684934
gsk-3684934
gtpl11100
A863152
DB11796
BCP13226
Q17001240
({3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-1-yl}methoxy)phosphonic acid
SB11250
fostemsavir; bms-663068
EX-A1973
864953-29-7(free base)
(3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-1-yl)methyl dihydrogen phosphate
NCGC00510187-01
fostemsavir & pg16
bms-626529 & 4dm2m
fostemsavir & pg16-imab
bms-626529 & 35o22
bms626-529 & nih45-46g54w
fostemsavir & nih45-46g54w
fostemsavir & 3bnc117
fostemsavir & ch106
bms-626529 & pgt128
bms-626529 & 3bnc117
fostemsavir & vrc03
bms-626529 & pg16
bms-626529 & vrc07-523
[3-[2-(4-benzoylpiperazin-1-yl)-2-oxo-acetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate
bms-626529 & pgt128-imab
fostemsavir & pgt128
fostemsavir & 35o22
fostemsavir & n6
bms-626529 & n6
fostemsavir & pgt128-imab
fostemsavir & 4dm2m
bms-626529 & pg16-imab
bms626-529 & vrc03
fostemsavir & vrc07-523
bms-626529 & ch106
1-(4-benzoyl-1-piperazinyl)-2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-ethanedione
EN300-20207550

Toxicity

ExcerptReference
" Primary endpoints were the proportion of patients with an HIV-1 RNA viral load less than 50 copies per mL (response rate) at week 24 and the frequency of serious adverse events and adverse events leading to discontinuation, up to the week 24 analysis."( Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Bogner, JR; Brinson, C; Diaconescu, IG; Echevarría, J; Fourie, J; Hanna, GJ; Joshi, SR; Lalezari, JP; Lataillade, M; Latiff, GH; Martins, M; Mendo Urbina, FC; Stock, DA; Sussmann Pena, OA; Thompson, M; Treviño-Pérez, S, 2015
)
" Serious adverse events were noted in 13 (7%) of 200 patients in the BMS-663068 groups and five (10%) of the 51 patients in the ritonavir-boosted atazanavir group."( Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Bogner, JR; Brinson, C; Diaconescu, IG; Echevarría, J; Fourie, J; Hanna, GJ; Joshi, SR; Lalezari, JP; Lataillade, M; Latiff, GH; Martins, M; Mendo Urbina, FC; Stock, DA; Sussmann Pena, OA; Thompson, M; Treviño-Pérez, S, 2015
)
" Endpoints for the week 96 interim analyses included the proportions of participants with plasma HIV-1 RNA of less than 40 copies per mL, changes from baseline in CD4 cell counts, and the frequency of adverse events, adverse events leading to discontinuation, and deaths."( Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Aberg, JA; Ackerman, P; Cahn, P; Castagna, A; Chabria, S; De Jesus, E; Diaz, RS; Gartland, M; Grinsztejn, B; Kozal, M; Kumar, PN; Lalezari, JP; Lataillade, M; Latiff, GH; Llamoso, C; Molina, JM; Moreno, S; Pialoux, G; Pierce, A; Thompson, M; Wang, M, 2020
)
" Few adverse events led to discontinuation (26 [7%] of 371)."( Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Aberg, JA; Ackerman, P; Cahn, P; Castagna, A; Chabria, S; De Jesus, E; Diaz, RS; Gartland, M; Grinsztejn, B; Kozal, M; Kumar, PN; Lalezari, JP; Lataillade, M; Latiff, GH; Llamoso, C; Molina, JM; Moreno, S; Pialoux, G; Pierce, A; Thompson, M; Wang, M, 2020
)
" at least 200 cells/μl had grade 3/4 adverse events [53/107 (50%) vs."( Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.
Aberg, J; Ackerman, P; Cassetti, I; Castagna, A; Chabria, S; Kozal, M; Kumar, PN; Lataillade, M; Latiff, GH; Llamoso, C; Martins, M; Molina, JM; Pialoux, G; Pierce, A; Ramgopal, M; Sprinz, E; Streinu-Cercel, A; Thompson, M; Treviño-Pérez, S; Wang, M, 2021
)

Pharmacokinetics

ExcerptReference
" Similarly, coadministration of BMS-663068 with RTV increased the BMS-626529 Cmax and AUCtau by 53% and 45%, respectively."( Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Bertz, R; Furlong, M; Hanna, GJ; Hruska, M; Hwang, C; Landry, IS; Shah, V; Zhu, L, 2015
)
"Study 206216 (NCT02666001) was a Phase I, open-label study, assessing the effect of FTR 600 mg (extended-release formulation) twice daily on pharmacokinetics of MET or BUP and norBUP, in non-HIV-infected participants on stable maintenance therapy with MET (40-120 mg; n = 16) or BUP plus naloxone (8-24 mg plus 2-6 mg; n = 16); pharmacodynamic response was assessed using standard opioid rating scales."( Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Ackerman, P; Chang, M; Llamoso, C; Lubin, S; Magee, M; Moore, K; Myers, E; Sevinsky, H, 2019
)
" Opioid pharmacodynamic scores were similar with and without MET/BUP with no symptoms of withdrawal/overdose; no new safety signal for FTR when combined with a stable opioid regimen."( Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Ackerman, P; Chang, M; Llamoso, C; Lubin, S; Magee, M; Moore, K; Myers, E; Sevinsky, H, 2019
)

Compound-Compound Interactions

ExcerptReference
" Opioid pharmacodynamic scores were similar with and without MET/BUP with no symptoms of withdrawal/overdose; no new safety signal for FTR when combined with a stable opioid regimen."( Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Ackerman, P; Chang, M; Llamoso, C; Lubin, S; Magee, M; Moore, K; Myers, E; Sevinsky, H, 2019
)
" FTR can be administered with MET or BUP without dose adjustment."( Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Ackerman, P; Chang, M; Llamoso, C; Lubin, S; Magee, M; Moore, K; Myers, E; Sevinsky, H, 2019
)
" FTR was administered with and without ritonavir (RTV), a protease inhibitor previously shown to boost TMR exposures."( Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects.
Ackerman, P; Gorycki, P; Magee, M; Miao, X; Moore, K, 2022
)
" Understanding drug-drug interactions (DDIs) is important in individuals taking fostemsavir with hormonal contraceptives or menopausal or gender-affirming hormonal therapies."( Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration.
Ackerman, P; Clark, A; Mageau, AS; Magee, M; Mannino, F; Moore, K; Nwokolo, N; Post, E; Shah, R, 2023
)

Bioavailability

ExcerptReference
" The prodrug is designed to overcome the solubility-limited bioavailability of the active moiety, BMS-626529."( Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.
Brown, J; Chien, C; Dennis, A; Doll, W; Grasela, D; Nettles, RE; Page, R; Sandefer, E; Timmins, P; Zhu, L, 2013
)
" Although it holds promise to be a first-in-class Env-targeted entry inhibitor for the clinic, issues with bioavailability relegate its use to salvage therapies only."( Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability.
Cocklin, S; Karadsheh, R; Meuser, ME, 2020
)
"Many lead compounds fail to reach clinical trials despite being potent because of low bioavailability attributed to their insufficient solubility making solubility a primary and crucial factor in early phase drug discovery."( Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Baidya, ATK; Das, B; Kumar, R; Mathew, AT; Yadav, AK, 2022
)
" Temsavir relative bioavailability of 2 low-dose fostemsavir extended-release formulations (3 × 200 mg; formulations A and B) and reference formulation (600 mg extended release) was assessed in a 2-part, open-label, randomized, crossover study in healthy adults."( Model-Based Dose Selection of Fostemsavir for Pediatric Populations With Multidrug-Resistant HIV-1 and Relative Bioavailability Assessment in Healthy Adults.
Abberbock, J; Chabria, S; Goyal, N; Jones, C; Magee, M; Moore, K; Taylor, J; Thakkar, N, 2023
)

Dosage Studied

BMS-663068 with ATV/r increased the BMS-626529 maximum concentration in plasma by 68% and 54%. AI438011 is an ongoing trial investigating the efficacy, safety, and dose-response of B MS-66 3068 in HIV-1-infected patients.

ExcerptReference
" Compared with the results obtained by administration of BMS-663068 alone, coadministration of BMS-663068 with ATV/r increased the BMS-626529 maximum concentration in plasma (Cmax) and the area under the concentration-time curve in one dosing interval (AUCtau) by 68% and 54%, respectively."( Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Bertz, R; Furlong, M; Hanna, GJ; Hruska, M; Hwang, C; Landry, IS; Shah, V; Zhu, L, 2015
)
" AI438011 is an ongoing trial investigating the efficacy, safety, and dose-response of BMS-663068 in treatment-experienced, HIV-1-infected patients."( Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Bogner, JR; Brinson, C; Diaconescu, IG; Echevarría, J; Fourie, J; Hanna, GJ; Joshi, SR; Lalezari, JP; Lataillade, M; Latiff, GH; Martins, M; Mendo Urbina, FC; Stock, DA; Sussmann Pena, OA; Thompson, M; Treviño-Pérez, S, 2015
)
" Exposure-response analyses showed a relationship between the loge-transformed concentration at the end of a dosing interval (Ctau) normalized for the protein binding-adjusted BMS-626529 half-maximal (50%) inhibitory concentration (PBAIC50) and the change in the HIV-1 RNA level from the baseline level after 7 days of BMS-663068 monotherapy."( Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Abu Tarif, M; Bertz, RJ; Boulton, DW; Hanna, GJ; Hruska, M; Joshi, S; Landry, I; Lataillade, M; Pitsiu, M; Sadler, BM; Zhu, L, 2016
)
" The phase 2b trial AI438011 investigated the safety, efficacy, and dose-response of fostemsavir vs ritonavir-boosted atazanavir (ATV/r) in treatment-experienced, HIV-1-infected subjects."( Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
Hanna, GJ; Joshi, SR; Krystal, M; Lataillade, M; Lee, S; Stock, DA; Zhou, N, 2018
)
"Following coadministration with FTR, dose-normalized MET (R-, S- and total) exposures (maximum concentration in plasma, area under the plasma concentration-time curve over the dosing interval and concentration in plasma at 24 hours) increased 9-15% and BUP and norBUP exposures increased 24-39%."( Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Ackerman, P; Chang, M; Llamoso, C; Lubin, S; Magee, M; Moore, K; Myers, E; Sevinsky, H, 2019
)
"Capsid inhibitors (CAI) demonstrate high potency and potential for extended-duration dosing in pre-clinical trials."( Novel Antiretroviral Agents.
Cambou, MC; Landovitz, RJ, 2020
)
" Dosing simulations demonstrated that twice-daily fostemsavir 600-mg (adult dose) and 400-mg doses met safety and efficacy criteria for 35 kg or greater and 20 or greater to less than 35 kg pediatric weight bands, respectively."( Model-Based Dose Selection of Fostemsavir for Pediatric Populations With Multidrug-Resistant HIV-1 and Relative Bioavailability Assessment in Healthy Adults.
Abberbock, J; Chabria, S; Goyal, N; Jones, C; Magee, M; Moore, K; Taylor, J; Thakkar, N, 2023
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1866020Thermodynamic aqueous solubility of the compound2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's21 (37.50)24.3611
2020's35 (62.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (23.21%)5.53%
Reviews15 (26.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]